[Effects of @entity668 on cell proliferation and @entity5447 expression of cardiac fibroblasts modulated by XXXX ].

@entity1831 @entity35 @entity2667 @entity5463 @entity19 @entity668 @entity2822 @entity7131 @entity98 @entity5447
OBJECTIVE: To study the effects of @entity668 , a @entity7131 ( @entity7131 ) inhibitor, on the cell proliferation and @entity5447 expression of cardiac fibroblasts (CFs) modulated by @entity5463 ( @entity1831 ) and to investigate the intracellular signal transduction mechanisms of @entity1831 in CFs. METHODS: The cultured CFs of neonatal @entity35 were divided into 3 groups: @entity1831 group (10(-7) mol/L @entity1831 was added into the culture), @entity668 group (10(-6) mol/L @entity668 and 10(-7) mol/L @entity1831 were added into the culture), and control group. @entity98 assay was used to evaluate the cell proliferation. The cultured cells were collected and @entity2667 was used to label the DNA so as to identify the cell cycle. Specific @entity19 -versus- @entity35 @entity5447 protein monoclonal antibody and @entity2822 -labeled secondary antibody were added into the cell suspension to label the @entity5447 protein in the cells. Flow cytometry was used to determine the distribution of cell cycles and @entity5447 expression. RESULTS: (1). The A value of CFs measured by @entity98 assay in @entity1831 + @entity668 group was 0.32 +/- 0.01, significantly lower than that of the @entity1831 group (0.39 +/- 0.01, P < 0.01). (2). The percentage of CFs in S stage was 4.4% +/- 1.7% in the @entity1831 + @entity668 group, lower than those of the @entity1831 group (15.5% +/- 1.4%, P < 0.01) and control group (7.5% +/- 1.0%). The PI of CFs was 20.9% +/- 1.2% in the @entity1831 + @entity668 group, significantly lower than that of the @entity1831 group (31.4% +/- 1.5%, P < 0.01). The PI of the @entity1831 group was significantly lower than that of the control group (26.0% +/- 1.0%, P < 0.01). The percentage of CFs in G(0)/G(1) stage was 79.1% +/- 1.2% in the @entity1831 + 1 @entity668 group, significantly higher than that in the @entity1831 group (68.6% +/- 1.5%, P < 0.01). The percentage of CFs in G(0)/G(1) stage in the @entity1831 group was significantly lower than that in the control group (74.0% +/- 1.0%, P < 0.01) too. (3). The expression rate of @entity5447 protein was 91.7% +/- 2.2% in the @entity1831 + @entity668 group, significantly higher than that in the @entity1831 group (63.3% +/- 1.9%, P < 0.01). CONCLUSION: @entity7131 inhibitor remarkably reverses the CFs proliferation and @entity5447 downregulation induced by @entity1831 . It may be involved in the intracellular signal transduction pathway of @entity1831 in CFs.
